Kenneth J. Kelley, Director at HALOZYME THERAPEUTICS INC (HALO), sold 15,000 shares at $10.56 ($158K) on 2007-05-18, disclosed to the SEC on 2007-05-22.
Scheduled sale ($158k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.55 | 8,800 | $93K | 58.6% |
| 2 | $10.56 | 1,400 | $15K | 9.3% |
| 3 | $10.56 | 4,800 | $51K | 32.0% |
| Total | $10.55 avg | 15,000 | $158K | 100% |
| Filing → |
| HALO | SELL | 2021-02-01 | $469K | — | Filing → |
| HALO | SELL | 2021-01-04 | $417K | — | Filing → |
| HALO | SELL | 2020-12-07 | $1.4M | — | Filing → |